Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-123242
Filing Date
2024-11-07
Accepted
2024-11-07 16:00:30
Documents
51
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q crdf-20240930.htm   iXBRL 10-Q 1526928
2 EX-31.1 crdf-ex31_1.htm EX-31.1 13321
3 EX-31.2 crdf-ex31_2.htm EX-31.2 13220
4 EX-32.1 crdf-ex32_1.htm EX-32.1 6575
5 EX-32.2 crdf-ex32_2.htm EX-32.2 6474
  Complete submission text file 0000950170-24-123242.txt   5965288

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT crdf-20240930.xsd EX-101.SCH 679094
53 EXTRACTED XBRL INSTANCE DOCUMENT crdf-20240930_htm.xml XML 1145342
Mailing Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121
Business Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121 858-952-7570
Cardiff Oncology, Inc. (Filer) CIK: 0001213037 (see all company filings)

EIN.: 272004382 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35558 | Film No.: 241435343
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)